CORE E: NOVEL TARGET DISCOVERY AND ASSAY

核心 E：新靶标发现和测定

• 批准号: 8641343
• 负责人: Julian P Whitelegge
• 金额: $ 21.67万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8641343
• 关键词: Address; Animal Experiments; Binding; Bioinformatics; Biological; Biological Assay; Biological Markers; Biological Process; Biology; Cells; Clinic; Clinical; Communication; Communities; Complement; Complications of Diabetes Mellitus; Computer software; Consult; Continuing Education; Data; Databases; Development; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Epigenetic Process; Foundations; Funding; Genetic; Genomics; Goals; Homologous Gene; Human; Human Genetics; Individual; Inflammatory; Institutes; Insulin; Insulin Resistance; Insulin-Like Growth-Factor-Binding Proteins; Ions; Knockout Mice; Label; Lead; Leadership; Learning; Length; Liquid Chromatography; Mass Spectrum Analysis; Measurement; Measures; Metabolic; Metabolism; Mission; Molecular; Monitor; Mus; Obesity; Outcome; Patients; Peptides; Performance; Physiology; Post-Translational Protein Processing; Prevention; Protein Analysis; Protein Isoforms; Proteins; Proteomics; Qualifying; Quality Control; Reaction; Reagent; Relative (related person); Research; Research Personnel; Resolution; Resources; Sampling; Services; Signal Transduction; Stable Isotope Labeling; Statistical Data Interpretation; Strategic Planning; Structure; System; Testing; Transgenic Organisms; Translating; Translations; Validation; assay development; biological systems; clinical assay development; clinically relevant; combat; cost effective; data mining; design; empowered; experience; high throughput screening; humanin; improved; interest; mass spectrometer; meetings; member; nano; novel; novel therapeutics; outreach; polyclonal antibody; research study; scaffold; statistics; synthetic peptide; tandem mass spectrometry

The Novel Target Discovery and Assay Development Core (NTDAC) will provide investigators at UCLA, UCSD, the Salk Institute and Cedars-Sinai with consultancy and a suite of state-of-the-art molecular measurements not available from other national resources. The new NTDAC core assembles a comprehensive and highly specialized core with expertize in biological mass spectrometry and proteomics (Julian Whitelegge, Director) and ELISA assay development (Pinchas Cohen, Co-Director). Strengths of this biomedical core include the extensive expertise ofthe core leadership in diabetes research, wide experience in protein and peptide analysis, access to bioinformatics resources, and the collegial outreach of NTDAC leadership to DRC investigators to assist in the strategic planning and execution of studies relevant to the DRC mission. Core goals include: 1) provide an accessible user interface toward meeting objectives in a timely, cost effective, and integrated manner individualized to the specific needs of each DRC investigator, 2) provide discovery mass spectrometry services with appropriate bioinformafics for sensitive, accurate measurements with quality control, 3) provide biomarker qualificafion, immunocapture and top-down mass spectrometry for qualification of lead proteins and peptides with respect to biological function, 4) provide assay construction for novel peptides and proteins, and optimization of reliable assays toward the clinic, 5) provide ELISA services for novel assays for development of new clinical assays for better pafient outcomes in diabetes. The collective and complementary expertise of the core leadership is outstanding and provides DRC invesfigators with an opportunity to explore and implement experimental strategies that rely upon direct analysis of proteins and peptides. The new NTDAC core provides discovery proteomics and peptidomics, alongside the lipidomics component that has been introduced into the MMPC (core B). The core will synergize with the other DRC cores through many favorable interactions including identification of interaction partners (core A), integrafion with metabolism and physiology studies (core B) and enhanced bioinformatics resources related to the genomics and genetics cores (C & D). Collectively, our ability to study the proteins and peptides of insulin action, substrate metabolism, and inflammatory signaling will drive the UCSD-UCLA DRC fonfl/ard in discovery of critical biological molecules involved in the pathobiology of obesity and insulin resistance, and provide a foundation for the development of novel therapeutic strategies to combat diabetes and diabetes complications.

新的目标发现和分析开发核心(NTDAC)将为加州大学洛杉矶分校的研究人员提供 加州大学圣迭戈分校、索尔克研究所和雪松-西奈大学提供咨询服务和一套最先进的分子 其他国家资源无法提供的测量数据。新的NTDAC核心组装了一个 全面、高度专业化的核心，具有生物质谱学和蛋白质组学方面的专业知识 (朱利安·怀特莱格，主任)和ELISA检测发展(Pinchas Cohen，联席主任)。这方面的优势 生物医学核心包括糖尿病研究核心领导层的广泛专业知识，丰富的经验 在蛋白质和多肽分析方面，获取生物信息学资源，以及NTDAC的大学外展 领导刚果(金)调查人员协助战略规划和执行与 刚果民主共和国任务。核心目标包括：1)提供可访问的用户界面，以便在 针对每个刚果民主共和国调查员的具体需求，采取及时、经济高效和综合的方式，2) 以适当的生物信息提供发现质谱学服务，以实现灵敏、准确 具有质量控制的测量，3)提供生物标志物鉴定、免疫捕获和自上而下的质量 根据生物功能鉴定铅蛋白和多肽的光谱分析，4)提供 新型多肽和蛋白质检测方法的构建及临床可靠检测方法的优化，5) 为开发新的临床检测方法提供酶联免疫吸附试验服务，以获得更好的结果 糖尿病患者。核心领导层的集体和互补的专业知识是杰出的，并提供了 DRC投资人有机会探索和实施依赖直接投资的实验战略 蛋白质和多肽的分析。新的NTDAC核心提供发现蛋白质组学和多肽组学， 与已被引入MMPC(核心B)的脂质组学成分一起。核心将会 通过许多有利的交互作用，包括确定交互作用，与其他DRC核心协同工作 伙伴(核心A)、新陈代谢和生理学研究一体化(核心B)和增强生物信息学 与基因组学和遗传学核心(C&D)相关的资源。总的来说，我们研究蛋白质的能力 胰岛素作用、底物代谢和炎症信号的多肽将驱动UCSD-UCLA DRC Fonfl/ard发现与肥胖和胰岛素病理生物学有关的关键生物分子 耐药性，并为开发抗击糖尿病的新治疗策略提供了基础 和糖尿病并发症。